Asset profile

QL1706

Multispecific antibody

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-08-31.

How the evidence outlook works ↗

Upcoming events

(25 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (2)
October 2026 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-10 · NCT07129161 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2026 (1)
Phase 2HR-positive/HER2-negative Breast CancerRecruiting
Est. primary completion 2026-12 · NCT07396324 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (18)
February 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-25 · NCT06897046 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2027 (1)
Phase 2Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination DeficiencyNot yet recruiting
Est. primary completion 2027-03-30 · NCT07113964 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

April 2027 (2)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04 · NCT07453394 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04 · NCT07139041 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

May 2027 (2)
Phase 2Triple-Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2027-05-30 · NCT07005583 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast Cancer, HR+/HER2- Breast CancerRecruiting
Est. primary completion 2027-05-31 · NCT06967103 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2027 (2)
Phase 2Intrahepatic Cholangiocarcinoma (Icc)Recruiting
Est. primary completion 2027-08-01 · NCT07070700 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-31 · NCT05487391 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

September 2027 (3)
Phase 2Advanced Breast CancerRecruiting
Est. primary completion 2027-09 · NCT07180160 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2TNBC, Triple Negative Breast CancerRecruiting
Est. primary completion 2027-09-15 · NCT07601178 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Triple-negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2027-09-30 · NCT07509515 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

October 2027 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10 · NCT07134413 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

November 2027 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-11-01 · NCT07197697 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (5)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07082179 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT07200947 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-18 · NCT07286942 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Lung AdenocarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07416058 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07246317 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2028 (3)
January 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-28 · NCT07330596 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

March 2028 (1)
Phase 3Small-cell Lung CancerNot yet recruiting
Est. primary completion 2028-03 · NCT06789796 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2028 (1)
Phase 2Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706Not yet recruiting
Est. primary completion 2028-12-30 · NCT07372079 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2029 (2)
February 2029 (1)
Phase 2Triple Negative Breast Cancer MetastaticNot yet recruiting
Est. primary completion 2029-02-10 · NCT07413601 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

June 2029 (1)
Phase 3Lung CancerActive not recruiting
Est. primary completion 2029-06 · NCT05690945 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.